Our findings are fully consistent with previous studies [5,6,7] and, for the first time, extend the positive association of Fetuin-A with NAFLD also to a group of patients with established atherosclerotic CVD. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.